Figure 11.
Inhibition of the JAK/STAT pathway mimics KrasG12Dinactivation-induced tissue repair. (A) Experimental design. iKras mice were given DOX and after 3 days acute pancreatitis was induced. After pancreatitis, KrasG12D was left ON for 3 weeks and at 3 weeks mice either received ruxolitinib (180 mg/kg) daily for 3 days or were treated with vehicle. N = 2–3 mice per group. (B) H&E, periodic acid–Schiff (PAS), and immunofluorescent staining for p-STAT3 (red), F4/80 (green), and SMA (white), or ARG1 (red), F4/80 (green), and CK19 (white). Scale bar: 50 μm. N = 2–3 mice per group. (C) Quantification for the p-STAT3 staining. (D) Quantification for the PAS staining. (E) Quantification of CK19-positive area. (F) Quantification of SMA-positive area. (G) Quantification of ARG1+-positive area within the F4/80+ macrophages. (H) Quantification of F4/80+-positive area. All data were analyzed using a t test. Blue, male; pink, females. Rux, ruxolitinib; Veh, vehicle.